Codexis to Report Third Quarter 2025 Financial Results on November 6
Codexis (NASDAQ: CDXS) will report third quarter 2025 financial results on Thursday, November 6, 2025, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Codexis (NASDAQ: CDXS) will report third quarter 2025 financial results on Thursday, November 6, 2025, after market close. Management will host a conference call and live webcast at 4:30 PM Eastern Time to discuss results and provide a business update.
Investors can access the live webcast on the Codexis Investor Relations website; the webcast will be archived for 90 days. A telephone replay will be available for 48 hours with access ID 13726635.
Details
News Market Reaction – CDXS
On Oct 23, the day this news came out, CDXS closed 1.17% above the previous close.
Data tracked by StockTitan Argus for the Oct 23 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced that it will report its financial results for the third quarter of 2025 on Thursday, November 6, 2025, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company’s financial results and provide a business update.
Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 201-689-8798 (international). A telephone replay of the call will be available for 48 hours by dialing 877-660-6853 (domestic) or 201-612-7415 (international), access ID #13726635.
About Codexis
Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit https://www.codexis.com.
For More Information
Georgia Erbez
Chief Financial Officer
Codexis, Inc.
(650) 421-8100
ir@codexis.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.